INmune Historical Cash Flow
| INMB Stock | USD 5.05 0.16 3.27% |
Analysis of INmune Bio cash flow over time is an excellent tool to project INmune Bio future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 0.0 or End Period Cash Flow of 23.6 M as it is a great indicator of INmune Bio ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining INmune Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether INmune Bio is a good buy for the upcoming year.
INmune |
About INmune Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in INmune balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which INmune's non-liquid assets can be easily converted into cash.
INmune Bio Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from INmune Bio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Change To Netincome is projected to increase significantly based on the last few years of reporting. The current year's Change To Liabilities is expected to grow to about 2.1 M, whereas Sale Purchase Of Stock is forecasted to decline to about 32.8 K.
| 2010 | 2023 | 2024 (projected) | Change Receivables | 229K | 206.1K | 183.2K | Depreciation | 126K | 224K | 216.0K |
INmune Bio cash flow statement Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 900K | 12.2M | (1.0M) | 81.4M | 34.5K | 32.8K | |
| Change In Cash | 6.8M | 15.0M | 52.8M | (22.7M) | (16.3M) | (15.5M) | |
| Total Cash From Operating Activities | (5.4M) | (8.9M) | (28.5M) | (22.7M) | (12.0M) | (12.6M) | |
| Change To Operating Activities | (129.2K) | (1.0M) | (5.3M) | (4.3M) | (3.8M) | (3.6M) | |
| Net Income | (7.7M) | (12.1M) | (30.3M) | (27.3M) | (30.0M) | (28.5M) | |
| Total Cash From Financing Activities | 12.2M | 23.9M | 96.4M | 729K | (4.2M) | (4.0M) | |
| End Period Cash Flow | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
| Change To Netincome | 4.1M | 3.1M | 4.8M | 7.1M | 8.2M | 8.6M | |
| Change To Liabilities | (131.7K) | 1.1M | 2.5M | 1.8M | 2.0M | 2.1M | |
| Free Cash Flow | (5.4M) | (8.9M) | (43.5M) | (22.7M) | (12.0M) | (12.6M) | |
| Change In Working Capital | (260.9K) | 43.5K | (3.1M) | (2.9M) | 10.4M | 11.0M | |
| Begin Period Cash Flow | 186.2K | 7.0M | 22.0M | 74.8M | 52.2M | 54.8M | |
| Other Non Cash Items | (1.5M) | 3.2M | 126K | 328K | 224K | 212.8K | |
| Stock Based Compensation | 4.1M | 3.1M | 4.8M | 7.1M | 7.4M | 5.8M | |
| Cash And Cash Equivalents Changes | 6.8M | 15.0M | 52.8M | (22.0M) | (25.3M) | (24.0M) | |
| Cash Flows Other Operating | (1.7M) | (1.0M) | (5.5M) | (4.8M) | (4.3M) | (4.1M) | |
| Issuance Of Capital Stock | 12.2M | 24.9M | 80.3M | 699K | 775K | 736.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.